TRMT1 Antibody

What is the optimal application range for TRMT1 antibodies?

TRMT1 antibodies demonstrate versatility across multiple experimental applications. Monoclonal antibodies like TRMT1 Antibody (G-3) effectively detect TRMT1 protein from mouse, rat, and human samples through western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA) . For optimal results, polyclonal antibodies like Proteintech's 14970-1-AP should be used at dilutions ranging from 1:600-1:3000 for WB, 1:50-1:500 for IHC, and 1:20-1:200 for IF/ICC applications . Always validate antibody performance in your specific biological system, as reactivity can vary between manufacturers.

How should TRMT1 antibodies be stored for maximum stability?

Most TRMT1 antibodies require storage at -20°C and remain stable for approximately one year after receipt . Polyclonal TRMT1 antibodies are typically supplied in PBS buffer with 0.02% sodium azide and 50% glycerol at pH 7.3, while some preparations may contain 0.1% BSA for smaller volume formats (20μl) . For antibodies like OriGene's TA346792, aliquoting is unnecessary when stored at -20°C . When handling during experiments, maintain antibodies on ice and avoid repeated freeze-thaw cycles that can compromise binding activity and specificity.

What is the typical molecular weight range observed for TRMT1 protein in western blotting?

While the calculated molecular weight of TRMT1 is 81 kDa, researchers typically observe bands at 72-75 kDa in western blotting experiments . This discrepancy between predicted and observed molecular weights should be considered when interpreting results. For example, Proteintech's 14970-1-AP antibody consistently detects TRMT1 at approximately 72 kDa , while Abcam's EPR25054-72 antibody (ab283652) detects a band at 75 kDa in HeLa cell lysates . When performing siRNA knockdown validation experiments, bands at approximately 100 kDa and 17 kDa may appear as non-specific signals , highlighting the importance of proper controls.

What controls should be included when validating TRMT1 antibody specificity?

Rigorous validation requires multiple complementary approaches. Primary validation should include TRMT1 siRNA knockdown experiments in relevant cell lines (such as HeLa cells) , comparing antibody reactivity between control and TRMT1-depleted samples. A properly validated antibody will show significant reduction in band intensity at the expected molecular weight (72-75 kDa) in knockdown samples. For immunoprecipitation applications, include a negative control using non-immune IgG of the same isotype as the TRMT1 antibody. When evaluating new antibody lots, consider comparing reactivity patterns with previously validated lots to ensure consistent performance across experiments.

How can TRMT1 antibodies be used to investigate SARS-CoV-2 Mpro-mediated cleavage of TRMT1?

Recent research has revealed that SARS-CoV-2 main protease (Mpro) recognizes and cleaves TRMT1 at a specific site (residues 527-534) . To study this phenomenon, researchers can:

• Perform in vitro cleavage assays with recombinant TRMT1 and Mpro, monitoring cleavage products using dual-domain recognizing antibodies targeting both the methyltransferase and zinc finger domains (anti-TRMT1 460-659), as well as single-domain recognizing antibodies specific for the zinc finger domain (anti-TRMT1 609-659) .

• For comparative analysis, utilize catalytically inactive Mpro (Cys145Ala) as a negative control that binds but does not cleave TRMT1 .

• Assess the functional consequences of cleavage through methyltransferase activity assays with radiolabeled S-[methyl-14C]-adenosyl methionine and tRNA binding capacity through electrophoretic mobility shift assays (EMSAs) .

This approach enables quantification of both cleavage efficiency and its impact on TRMT1 function, providing insights into how viral proteases may subvert host tRNA modification systems during infection.

What methodological approaches can distinguish between TRMT1 and TRMT1L paralogs using antibodies?

Vertebrates uniquely possess both TRMT1 and its paralog TRMT1L, which have distinct cellular localizations and enzymatic activities . To differentiate these paralogs:

• Select antibodies with minimal cross-reactivity by choosing those targeting non-conserved epitopes. While both proteins contain SAM-binding methyltransferase domains and zinc-finger motifs, they have different subcellular localizations that can aid in distinction - TRMT1 localizes to the nucleoplasm and mitochondria, while TRMT1L is enriched in the nucleolus .

• Employ CRISPR gene editing to generate TRMT1 or TRMT1L knockout cell lines as specificity controls, confirming antibody specificity through western blotting of knockout versus wild-type cells .

• Use subcellular fractionation followed by western blotting to differentiate between the paralogs based on their distinct localizations. Alternatively, perform co-immunofluorescence with antibodies targeting nucleolar markers (for TRMT1L) and mitochondrial markers (for TRMT1) .

This multi-layered approach enables reliable distinction between these functionally divergent paralogs in research applications.

How can TRMT1 antibodies be utilized to investigate disease-associated TRMT1 variants?

TRMT1 variants are associated with autosomal-recessive intellectual disability disorders . To investigate these variants:

• Employ immunoprecipitation with TRMT1 antibodies followed by mass spectrometry to analyze potential alterations in TRMT1 protein-protein interactions in patient-derived cells compared to controls.

• Combine TRMT1 immunoprecipitation with tRNA modification analysis to correlate protein levels with enzymatic activity. This can be accomplished by IP-LC-MS/MS to quantify m2,2G modification levels in tRNAs from patient cells.

• Perform immunofluorescence with TRMT1 antibodies to assess potential changes in subcellular localization of disease-associated variants, particularly examining nucleoplasmic versus mitochondrial distribution patterns.

This comprehensive approach enables researchers to connect genotype to molecular phenotype in TRMT1-associated disorders, potentially revealing disease mechanisms beyond simple loss of enzyme activity.

What are the optimal conditions for immunoprecipitating TRMT1 using available antibodies?

For successful TRMT1 immunoprecipitation, consider the following protocol optimizations:

• Antibody selection: Use antibodies specifically validated for IP applications. Abcam's ab186019 has been validated for immunoprecipitating TRMT1 from human samples at a concentration of 6 μg antibody per mg of cell lysate .

• Lysis conditions: Prepare cell lysates in non-denaturing buffers containing 1% NP-40 or 0.5% Triton X-100, 150 mM NaCl, 50 mM Tris-HCl (pH 7.5), and protease inhibitors.

• Pre-clearing step: Pre-clear lysates with protein A/G beads for 1 hour at 4°C to reduce non-specific binding.

• Antibody incubation: Incubate pre-cleared lysates with the TRMT1 antibody overnight at 4°C under gentle rotation to maximize antigen-antibody interaction.

• Detection method: For western blot analysis of immunoprecipitated TRMT1, load approximately 20% of the IP material per lane, and detect using a different TRMT1 antibody than the one used for IP to avoid heavy and light chain interference .

This optimized approach enables efficient isolation of TRMT1 protein complexes for downstream functional analyses.

How can TRMT1 antibodies be employed to analyze TRMT1 expression patterns in different tissues and cellular compartments?

TRMT1 exhibits distinct subcellular localization patterns due to its nuclear localization sequence and mitochondrial targeting signal . To comprehensively analyze expression patterns:

• For tissue-specific expression: Perform immunohistochemistry on tissue microarrays using TRMT1 antibodies at optimized dilutions (1:50-1:500 for polyclonal antibodies) . For human colon cancer tissue, use TE buffer (pH 9.0) for antigen retrieval, though citrate buffer (pH 6.0) can serve as an alternative .

• For subcellular localization: Employ subcellular fractionation followed by western blotting to quantitatively assess TRMT1 distribution between nuclear, mitochondrial, and cytosolic fractions. Alternatively, perform co-immunofluorescence with compartment-specific markers.

• For high-resolution imaging: Utilize super-resolution microscopy with fluorophore-conjugated TRMT1 antibodies, such as TRMT1 Antibody (G-3) FITC (sc-373687 FITC) or Alexa Fluor conjugates , to visualize precise subcellular localization patterns.

This multi-modal approach provides complementary perspectives on TRMT1 distribution across tissues and subcellular compartments, revealing potential tissue-specific functions.

What strategies can optimize TRMT1 detection in challenging experimental contexts?

Some experimental systems present challenges for TRMT1 detection. Optimize detection using these approaches:

• For low abundance detection: Use signal amplification methods such as tyramide signal amplification (TSA) with HRP-conjugated TRMT1 antibodies like sc-373687 HRP . Alternatively, employ highly sensitive chemiluminescent substrates with extended exposure times.

• For samples with high background: Implement stringent blocking (5% non-fat dry milk in TBST) and consider using monoclonal antibodies like EPR25054-72 to minimize non-specific binding. For problematic samples, incorporate additional washing steps with increased detergent concentration.

• For dual-protein detection: When studying TRMT1 interactions with binding partners, employ proximity ligation assays (PLA) using primary antibodies from different host species to visualize protein-protein interactions with single-molecule sensitivity.

• For fixed tissue samples: When working with paraffin-embedded sections, optimize antigen retrieval conditions experimentally, testing both heat-induced epitope retrieval with citrate buffer (pH 6.0) and Tris-EDTA buffer (pH 9.0) .

These advanced approaches enable reliable TRMT1 detection even in challenging experimental contexts.

How are TRMT1 antibodies contributing to understanding TRMT1's role in tRNA modification and protein synthesis?

Recent research utilizing TRMT1 antibodies has revealed critical insights into tRNA modification mechanisms:

• Differential targets of TRMT1 and TRMT1L: Studies using CRISPR-generated knockout cell lines combined with TRMT1 antibody validation have demonstrated that TRMT1 methylates all tRNAs containing guanosine at position 26, while TRMT1L specifically catalyzes m2,2G at position 27 in tyrosine tRNAs .

• Impact on translation: TRMT1 antibodies have enabled researchers to correlate TRMT1 protein levels with global protein synthesis rates, demonstrating that TRMT1-catalyzed tRNA modifications are essential for maintaining translation levels of proteins involved in cellular growth, development, and stress response .

• Disease relevance: Immunoblotting with TRMT1 antibodies in patient-derived cells has revealed that TRMT1 variants associated with intellectual disability disorders exhibit reduced protein levels, connecting genotype to molecular phenotype .

These findings highlight how TRMT1 antibodies serve as crucial tools in deciphering the complex relationship between tRNA modification, translation regulation, and human disease.

What methodological approaches can assess the impact of SARS-CoV-2 infection on TRMT1 function?

The discovery that SARS-CoV-2 Mpro cleaves TRMT1 has opened new research avenues requiring specialized antibody applications:

• Temporal analysis during infection: Use time-course experiments with TRMT1 antibodies detecting both full-length and cleaved forms to monitor TRMT1 proteolysis kinetics during viral infection.

• Functional impact assessment: Combine immunoprecipitation of TRMT1 from infected cells with tRNA binding and methyltransferase activity assays to correlate cleavage with functional deficits.

• Structural analysis: Employ epitope-specific antibodies targeting regions flanking the Mpro cleavage site (residues 527-534) to monitor structural alterations in TRMT1 following viral infection.

• Therapeutic screening: Utilize TRMT1 cleavage as a readout for evaluating potential Mpro inhibitors, using western blotting with dual-domain recognizing antibodies to quantify protection from proteolysis.

These approaches enable researchers to understand how viral targeting of host tRNA modification systems may contribute to COVID-19 pathogenesis and potentially identify new therapeutic strategies.

How can TRMT1 antibodies be used to investigate the relationship between tRNA modification and redox stress?

Studies have revealed that TRMT1 knockdowns exhibit hypersensitivity to redox stress , suggesting a connection between tRNA modification and cellular redox homeostasis. To investigate this relationship:

• Combine oxidative stress induction with immunofluorescence using TRMT1 antibodies to monitor potential changes in TRMT1 localization or protein levels in response to redox challenges.

• Perform co-immunoprecipitation with TRMT1 antibodies under normal and oxidative stress conditions to identify stress-dependent interaction partners that may connect tRNA modification to redox response pathways.

• Implement ChIP-seq or CLIP-seq approaches with TRMT1 antibodies to identify potential changes in TRMT1 genomic or transcriptomic binding patterns under oxidative stress conditions.

• Correlate TRMT1 protein levels (detected by western blotting) with measurements of cellular redox state markers to establish quantitative relationships between TRMT1 abundance and redox homeostasis.

This multifaceted approach could reveal previously unrecognized connections between epitranscriptomic regulation and cellular stress response mechanisms.

What are the key differences between monoclonal and polyclonal TRMT1 antibodies for research applications?

Researchers should select antibody formats based on experimental requirements:

For applications requiring absolute specificity, such as distinguishing between TRMT1 and TRMT1L, monoclonal antibodies may be preferable. For maximum sensitivity in detecting low-abundance TRMT1, polyclonal antibodies often provide superior signal amplification through multi-epitope recognition.

What methodological considerations are important when selecting TRMT1 antibodies for specific research applications?

When selecting TRMT1 antibodies, consider these application-specific factors:

• For western blotting:

  • Select antibodies validated specifically for WB applications with demonstrated specificity at the expected molecular weight (72-75 kDa)

  • Consider detection method compatibility (chemiluminescence vs. fluorescence)

  • Verify sample type compatibility (human, mouse, rat) based on experimental requirements

• For immunohistochemistry:

  • Choose antibodies validated for IHC applications with optimized antigen retrieval protocols

  • Consider tissue type compatibility and fixation method requirements

  • Verify whether the antibody works with paraffin-embedded (IHCP) or frozen sections

• For immunoprecipitation:

  • Select antibodies specifically validated for IP applications, such as ab186019

  • Consider antibody binding affinity and concentration requirements

  • Verify compatibility with downstream applications (mass spectrometry, activity assays)

• For advanced applications (ChIP, PLA, multiplexing):

  • Evaluate host species compatibility with other antibodies in multiplexed experiments

  • Consider epitope accessibility in native protein complexes

  • Assess conjugate availability for specialized detection methods

This tailored selection approach ensures optimal antibody performance for each specific research application.